3SBio hits the big time with $6 billion cancer drug deal
The pharma giant Pfizer has bought international rights to the experimental cancer therapy and will take a $100 million equity stake in the Chinese drug developer Key Takeaways: The mega…
Will Trump’s drug order put the brakes on China’s overseas pharma drive?
The U.S. president has promised to reduce prescription drug prices by 30% to 80% for Americans, insisting they are entitled to prices paid in other developed countries Key Takeaways: Pharma…
Investors cheer Akeso’s revenue milestone, even as it returns to the red
The drugmaker’s shares rallied after the release of its strong annual report, up by a cumulative 18% over the next three trading days Key Takeaways: Akeso’s drug sales rose 25%…
With no cure in sight, drugs firm LianBio begins exit strategy
The biotech, which obtained rights to novel drugs for use in the Chinese market, has announced a plan to wind up its business and delist from the Nasdaq just four…
Everest reaches new heights on growing drug sales
The innovative drug maker said its revenue soared more than 850% last year to between 124 million yuan and 126 million yuan Key Takeaways: Everest Medicines’ revenue soared nine-fold last…
HBM gets health boost from drug licensing deals
The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer Key Takeaways: Nona Biosciences, a subsidiary of…
CHINA BULLETIN: Europe Calls on China
In this week’s issue EU leaders come calling on China, Evergrande restructures and Airbus invests. On a scale of 1 to 10, we give the week a 5 for offshore-listed China stocks.
Recent Articles
RECENT ARTICLES
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK -
Haitian looks for new financial flavor in Hong Kong IPO
603288.SHG
-
Ultraman lifts Bloks Group to new heights in first post-IPO report
0325.HK
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
